Sema4 completed the acquisition of GeneDx from OPKO Health for $623m.

Sema4, an AI-driven genomic and clinical data intelligence platform company, completed the acquisition of GeneDx, a provider of genomic testing and analysis, from OPKO Health, a multinational biopharmaceutical and diagnostics company, for $623m. "This acquisition gives us the opportunity to accelerate the use of genomics as standard of care by providing a deeper menu of precision medicine solutions to our health system partners to better meet their clinical needs," Eric Schadt, Sema4 Founder and CEO.